Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 56

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 56
---
 employed for an additional nine months following March 31, 2025, as if each award vested on a monthly basis without regard to the original vesting schedule, which option awards will remain exercisable until the earlier of the expiration of the term of such options or nine months from the effective date of her separation. In addition, in the event of a change in control within three months following the expiration of her consulting term, in lieu of the foregoing separation benefits, Dr. Koehler will be entitled to receive the severance benefits she would otherwise be entitled to under her employment agreement upon a change in control, as described above under “Potential Payments and Benefits upon Termination or Change in Control;” provided, however, that if the Company enters into a definitive agreement during the three month period after the expiration of the consulting term that would result in a change in control after the expiration of that three month period, the three month period will automatically be extended to until the change in control occurs.

Michael Zinda, Ph.D.

We entered into an employment agreement with Dr. Zinda in August 2017, effective June 14, 2017, in connection with his appointment as our Executive Vice President, Head of Research and Development from June 2017 to December 2018. He subsequently was promoted to the role of our Executive Vice President, Chief Scientific Officer effective January 1, 2019. In June 2020, we entered into a new employment agreement with Dr. Zinda which became effective upon the execution of the underwriting agreement for our IPO. Pursuant to his June 2020 employment agreement, Dr. Zinda was initially entitled to an annual base salary of $415,000, an annual target bonus with a target amount equal to 40% of his annual base salary and certain severance benefits, as described below under “—Potential Payments and Benefits upon Termination or Change of Control.” To qualify for the annual target bonus set at a percentage of his adjusted base salary in respect of any calendar year, Dr. Zinda must remain continuously employed with us through the 15th day of February of the following year. Dr. Zinda is also eligible for additional equity awards under our equity compensation plans, as may be granted from time to time. In July 2023, we amended Dr. Zinda’s June 2020 employment agreement to reflect updated termination of employment and change in control provisions to cover granted RSU awards.**

<div align='center'>40</div>

Potential Payments and Benefits upon Ter